PA8782301A1 - Tratamiento de leucemia resistente al imatinte - Google Patents

Tratamiento de leucemia resistente al imatinte

Info

Publication number
PA8782301A1
PA8782301A1 PA20088782301A PA8782301A PA8782301A1 PA 8782301 A1 PA8782301 A1 PA 8782301A1 PA 20088782301 A PA20088782301 A PA 20088782301A PA 8782301 A PA8782301 A PA 8782301A PA 8782301 A1 PA8782301 A1 PA 8782301A1
Authority
PA
Panama
Prior art keywords
impact resistant
resistant leukemia
leukemia treatment
treatment
quinolinacarbonitrilos
Prior art date
Application number
PA20088782301A
Other languages
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8782301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8782301A1 publication Critical patent/PA8782301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS 4 - ANILINO -3-QUINOLINACARBONITRILOS ÚTILES PARA TRATAR UN SUJETO QUE TIENE UNA LEUCEMIA POSITIVA BCRABL QUE ES RESISTENTE AL IMATINIB.
PA20088782301A 2007-06-01 2008-05-30 Tratamiento de leucemia resistente al imatinte PA8782301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01

Publications (1)

Publication Number Publication Date
PA8782301A1 true PA8782301A1 (es) 2009-01-23

Family

ID=39639071

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088782301A PA8782301A1 (es) 2007-06-01 2008-05-30 Tratamiento de leucemia resistente al imatinte

Country Status (24)

Country Link
US (1) US11103497B2 (es)
EP (4) EP2777704A3 (es)
JP (3) JP5888853B2 (es)
KR (1) KR101493543B1 (es)
CN (1) CN101686973B (es)
AU (1) AU2008260070B9 (es)
BR (1) BRPI0812355A2 (es)
CA (3) CA2868899C (es)
CL (1) CL2008001577A1 (es)
CY (2) CY1115251T1 (es)
DK (2) DK2478905T3 (es)
ES (2) ES2477567T3 (es)
HK (1) HK1142812A1 (es)
HU (1) HUE055524T2 (es)
IL (1) IL202407A0 (es)
MX (1) MX2009013069A (es)
PA (1) PA8782301A1 (es)
PL (2) PL3002009T3 (es)
PT (2) PT2478905E (es)
RU (1) RU2464026C2 (es)
SI (2) SI2478905T1 (es)
TW (1) TW200908982A (es)
WO (1) WO2008150957A2 (es)
ZA (1) ZA200908480B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200908982A (en) * 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia
CA2829131C (en) 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
KR20220052333A (ko) * 2019-08-22 2022-04-27 바이오하벤 테라퓨틱스 리미티드 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
EP2290056A3 (en) 2001-10-05 2011-06-01 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
JP2008539241A (ja) 2005-04-25 2008-11-13 ファイザー インコーポレイティッド ミオスタチンに対する抗体
CA2608333A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
WO2007011765A2 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US20100029676A1 (en) * 2005-11-04 2010-02-04 Sawyers Charles L T315a and f317i mutations of bcr-abl kinase domain
TW200908982A (en) 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia

Also Published As

Publication number Publication date
JP2010529038A (ja) 2010-08-26
EP3002009A2 (en) 2016-04-06
ES2477567T3 (es) 2014-07-17
EP3002009B1 (en) 2021-07-07
HUE055524T2 (hu) 2021-11-29
BRPI0812355A2 (pt) 2015-01-27
JP2016074700A (ja) 2016-05-12
US20080318971A1 (en) 2008-12-25
EP2152267A2 (en) 2010-02-17
JP2014111629A (ja) 2014-06-19
CY1115251T1 (el) 2017-01-04
US11103497B2 (en) 2021-08-31
WO2008150957A3 (en) 2009-08-06
CN101686973A (zh) 2010-03-31
DK2478905T3 (da) 2014-06-30
PL2478905T3 (pl) 2014-10-31
CN101686973B (zh) 2013-06-19
AU2008260070A1 (en) 2008-12-11
AU2008260070B2 (en) 2011-08-18
ZA200908480B (en) 2010-08-25
CL2008001577A1 (es) 2008-07-25
PT2478905E (pt) 2014-07-16
EP2478905B1 (en) 2014-05-14
SI3002009T1 (sl) 2021-09-30
EP2777704A3 (en) 2015-01-21
TW200908982A (en) 2009-03-01
IL202407A0 (en) 2010-06-30
CA2688467C (en) 2015-05-12
JP5888853B2 (ja) 2016-03-22
KR20100017983A (ko) 2010-02-16
EP2478905A3 (en) 2013-01-16
EP2478905A2 (en) 2012-07-25
PL3002009T3 (pl) 2021-12-13
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
HK1142812A1 (en) 2010-12-17
EP3002009A3 (en) 2016-07-06
WO2008150957A2 (en) 2008-12-11
RU2009144128A (ru) 2011-07-20
KR101493543B1 (ko) 2015-02-13
RU2464026C2 (ru) 2012-10-20
CY1124391T1 (el) 2022-07-22
CA2868899C (en) 2017-06-13
CA2964162A1 (en) 2008-12-11
AU2008260070B9 (en) 2012-01-19
MX2009013069A (es) 2010-03-17
PT3002009T (pt) 2021-08-02
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
EP2777704A2 (en) 2014-09-17
CA2964162C (en) 2019-12-31
CA2688467A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
BRPI0813966A8 (pt) Usos de mdl-1
CR20110492A (es) Compuestos tetracíclicos
MA32938B1 (fr) Composes organiques
MX2009011456A (es) Aumento de la productividad de las plantas por combinacion de agentes quimicos con modificaciones transgenicas.
UY33756A (es) Compuesto biciclico
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
CR9301S (es) Cuerpo de grifo
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY31688A1 (es) Plaguicidas
PA8772701A1 (es) "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA"
MX2010005114A (es) Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos.
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
MX2009005631A (es) Sulfuro de zinc transparente que tiene alta area superficial especifica.
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2009009490A (es) Profarmacos novedosos.
CL2007000773A1 (es) Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
UY31704A (es) Compuesto heterociclico fusionado